Additional Relevant Details The Aorfix Endovascular Stent Graft was featured in the “Improving EVAR Treatment by using Aorfix” symposium chaired by Dr. Toshihisa Asakura, Associate Professor of the Department of Cardiovascular Surgery, Saitama Medical University International Medical Center.  Dr. Asakura commented, “I am very impressed by the unique design, flexibility and conformability of Aorfix.  It has the only indication for use in standard and in challenging anatomies with highly angulated aortic necks.  In my personal experience, it performs extremely well and the results are very encouraging.  I really look forward to using the new IntelliFlex LP delivery system as soon as it becomes available in Japan.”
Dr. Naoki Toya, Vascular Surgeon at the Jikei University Kashiwa Hospital, Chiba, presented “Why I Use Aorfix” which addressed the Aorfix product design, the PYTHAGORAS clinical trial data, and his own series of 30 cases.  Dr. Toya commented, “The global data on Aorfix is exceptional with results being equivalent to other stent graft technologies, despite the more challenging anatomies and sicker patients that tend to be treated with Aorfix.  In my own series of 30 patients, there were no T1/T3 leaks or migration, with good sac shrinkage in more than 45% of cases at 6 month follow. My experience and data have convinced me that Aorfix is safe and reliable, and is more than capable of treating a broad range of anatomies, increasing the number of patients I can treat with minimally invasive endovascular repair.”Dr. Toya also presented the new IntelliFlex Low Profile (LP) delivery system anticipated for launch in Japan in early 2017.  This presentation included a video of the “First In Man” case performed by Professor Andrew Holden in Auckland, New Zealand, in November 2015.Mr. Masataka Hirata, President of Medico's Hirata, Lombard’s distribution partner in Japan, added, “We are pleased to see the continued adoption and expansion of Aorfix by the endovascular surgical community across Japan.  We have achieved more than 7.5% market share in just 18 months since commercial launch and we believe with the planned introduction of the new IntelliFlex LP delivery system, the adoption of the uniquely approved Aorfix stent graft will continue to accelerate.”